Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123331 | 0.88 | WDR5 (0.34) | WDR5NTRK1GPR3MAOAMAOB | |
| SCHEMBL7125867 | 0.81 | GPR3 (0.32) | NTRK1GPR3 | |
| SCHEMBL7118953 | 0.79 | GPR3 (0.41) | WDR5NTRK1GPR3MAOAMAOB | |
| SCHEMBL7122455 | 0.79 | GPR3 (0.41) | WDR5NTRK1GPR3MAOAMAOB | |
| SCHEMBL7119587 | 0.77 | WDR5 (0.39) | WDR5NTRK1GPR3MAOAMAOB | |
| SCHEMBL7122261 | 0.77 | WDR5 (0.39) | WDR5NTRK1GPR3MAOAMAOB | |
| SCHEMBL3994179 | 0.76 | HTR2A (0.42) | GPR3 | |
| SCHEMBL8439620 | 0.74 | HTR2A (0.41) | GPR3 | |
| SCHEMBL7122526 | 0.74 | IL1R1 (0.34) | ALDH1A1HPGDMAPT | |
| SCHEMBL7124382 | 0.74 | NTRK1 (0.33) | WDR5NTRK1GPR3MAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030148877-A1 | Metallocenes and catalysts for olefin-polymerisation | BASELL TECHNOLOGY COMPANY BV (NL) | 2003-08-07 | — | — | US | disclosed |
| EP-0952978-B1 | METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION | BASELL POLYOLEFINE GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-6451724-B1 | BIS(N-METHYL-5,10-DIHYDROINDENO(1,2-B)INDOL-10 -YL)TITANIUM DICHLORIDE | BASELL TECHNOLOGY COMPANY BV (NL) | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148877-A1 | Metallocenes and catalysts for olefin-polymerisation | MT-CO1, CPNE4, MT-CO3 | WDR5 4206/4885NTRK1 3468/4885GPR3 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.